A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study

European Neuropsychopharmacology

Volumn 22, Issue 7, 2012, Pages 469-481

  Koychev, Ivan ^a   McMullen, Katrina ^b   Lees, Jane ^a   Dadhiwala, Rukiya ^c   Grayson, Lois ^b,d   Perry, Charlotte ^d   Schmechtig, Anne ^b   Walters, James ^d   Craig, Kevin J ^e   Dawson, Gerard R ^e   Dourish, Colin T ^e   Ettinger, Ulrich ^f   Wilkinson, Lawrence ^d,g   Williams, Steven ^b   Deakin, John Francis William ^a   Barkus, Emma ^a,h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF MUNICH   (Germany)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Amisulpride; Biomarkers; Cognition; Risperidone; Schizophrenia; Schizotypy

Indexed keywords

AMISULPRIDE; NICOTINE; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTERSITE RELIABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELIABILITY; SCHIZOPHRENIA; SCHIZOTYPY; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SPATIAL MEMORY; SPATIAL WORKING MEMORY; VERBAL COMMUNICATION; VERBAL FLUENCY; WORKING MEMORY;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PERSONALITY INVENTORY; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SCHIZOTYPAL PERSONALITY DISORDER; SULPIRIDE; VERBAL BEHAVIOR; YOUNG ADULT;

EID: 84861480429     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.10.005     Document Type: Article

References (67)

1. Albus M., Hubmann W., Scherer J., Dreikorn B., Hecht S., Sobizack N., Mohr F. A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2002, 252(6):262-267.
2. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch. Gen. Psychiatry 1977, 34(10):1229-1235.
3. Barch D.M. Pharmacological manipulation of human working memory. Psychopharmacology (Berl.) 2004, 174(1):126-135.
4. Barkus E., Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol. Med. 2008, 38(9):1267-1276.
5. Barkus E., Murray R.M. Substance use in adolescence and psychosis: clarifying the relationship. Annu. Rev. Clin. Psychol. 2010, 6:365-389.
6. Burton S.C. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J. Psychiatr. Pract. 2005, 11(6):369-378.
7. Butler P.D., Martinez A., Foxe J.J., Kim D., Zemon V., Silipo G., Mahoney J., Shpaner M., Jalbrzikowski M., Javitt D.C. Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments. Brain 2007, 130(Pt 2):417-430.
8. Calkins M.E., Curtis C.E., Grove W.M., Iacono W.G. Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients. Schizophr. Bull. 2004, 30(2):317-325.
9. Chen W.J., Hsiao C.K., Lin C.C. Schizotypy in community samples: the three-factor structure and correlation with sustained attention. J. Abnorm. Psychol. 1997, 106(4):649-654.
10. Compton M.T., Chien V.H. No association between psychometrically-determined schizotypy and olfactory identification ability in first-degree relatives of patients with schizophrenia and non-psychiatric controls. Schizophr. Res. 2008, 100(1-3):216-223.
11. Erlenmeyer-Kimling L., Rock D., Roberts S.A., Janal M., Kestenbaum C., Cornblatt B., Adamo U.H., Gottesman I.I. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am. J. Psychiatry 2000, 157(9):1416-1422.
12. Esterberg M.L., Jones E.M., Compton M.T., Walker E.F. Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls. Schizophr. Res. 2007, 97(1-3):6-13.
13. Fuller R.L., Luck S.J., McMahon R.P., Gold J.M. Working memory consolidation is abnormally slow in schizophrenia. J. Abnorm. Psychol. 2005, 114(2):279-290.
14. Fuller R.L., Luck S.J., Braun E.L., Robinson B.M., McMahon R.P., Gold J.M. Impaired visual working memory consolidation in schizophrenia. Neuropsychology 2009, 23(1):71-80.
15. Gray J.A., Roth B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 2007, 12(10):904-922.
16. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J. Clin. Psychiatry 2006, 67(10):e12.
17. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
18. Haenschel C., Bittner R.A., Haertling F., Rotarska-Jagiela A., Maurer K., Singer W., Linden D.E. Contribution of impaired early-stage visual processing to working memory dysfunction in adolescents with schizophrenia: a study with event-related potentials and functional magnetic resonance imaging. Arch. Gen. Psychiatry 2007, 64(11):1229-1240.
19. Hardt J., Franke P. Validity, reliability and objectivity of the family history method in psychiatry: a meta analysis. Eur. Psychiatry 2007, 22(1):49-58.
20. Hartman M., Steketee M.C., Silva S., Lanning K., McCann H. Working memory and schizophrenia: evidence for slowed encoding. Schizophr. Res. 2003, 59(2-3):99-113.
21. Harvey P.D., Ogasa M., Cucchiaro J., Loebel A., Keefe R.S. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 2011, 127(1-3):188-194.
22. Heinrichs R.W. The primacy of cognition in schizophrenia. Am. Psychol. 2005, 60(3):229-242.
23. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
24. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., Fleischhacker W.W. Patient outcomes in schizophrenia II: the impact of cognition. Eur. Psychiatry 2005, 20(5-6):395-402.
25. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C., Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(23):13432-13437.
26. Hurko O. The uses of biomarkers in drug development. Ann. N. Y. Acad. Sci. 2009, 1180:1-10.
27. Hurko O. Future drug discovery and development. Mol. Genet. Metab. 2010, 100(Suppl. 1):S92-S96.
28. Keefe R.S., Fox K.H., Harvey P.D., Cucchiaro J., Siu C., Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr. Res. 2010, 125(2-3):161-168.
29. Kern R.S., Gold J.M., Dickinson D., Green M.F., Nuechterlein K.H., Baade L.E., Keefe R.S., Mesholam-Gately R.I., Seidman L.J., Lee C., Sugar C.A., Marder S.R. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr. Res. 2011, 126(1-3):124-131.
30. Kirrane R.M., Mitropoulou V., Nunn M., New A.S., Harvey P.D., Schopick F., Silverman J., Siever L.J. Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder. Neuropsychopharmacology 2000, 22(1):14-18.
31. Koychev I., El-Deredy W., Haenschel C., Deakin J.F. Visual information processing deficits as biomarkers of vulnerability to schizophrenia: an event-related potential study in schizotypy. Neuropsychologia 2010, 48(7):2205-2214.
32. Kremen W.S., Faraone S.V., Toomey R., Seidman L.J., Tsuang M.T. Sex differences in self-reported schizotypal traits in relatives of schizophrenic probands. Schizophr. Res. 1998, 34(1-2):27-37.
33. Lee J., Park S. Working memory impairments in schizophrenia: a meta-analysis. J. Abnorm. Psychol. 2005, 114(4):599-611.
34. Leeson V.C., Sharma P., Harrison M., Ron M.A., Barnes T.R., Joyce E.M. IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. Schizophr. Bull. 2009, 37(4):768-777.
35. Lencz T., Bilder R.M., Turkel E., Goldman R.S., Robinson D., Kane J.M., Lieberman J.A. Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. Arch. Gen. Psychiatry 2003, 60(3):238-243.
36. Lenzenweger M.F. Schizotaxia, schizotypy, and schizophrenia: Paul E. Meehl's blueprint for the experimental psychopathology and genetics of schizophrenia. J. Abnorm. Psychol. 2006, 115(2):195-200.
37. Luciana M., Collins P.F., Depue R.A. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb. Cortex 1998, 8(3):218-226.
38. Mammarella N., Altamura M., Padalino F.A., Petito A., Fairfield B., Bellomo A. False memories in schizophrenia? An imagination inflation study. Psychiatry Res. 2010, 179(3):267-273.
39. Matheson S., Langdon R. Schizotypal traits impact upon executive working memory and aspects of IQ. Psychiatry Res. 2008, 159(1-2):207-214.
40. McClure M.M., Harvey P.D., Goodman M., Triebwasser J., New A., Koenigsberg H.W., Sprung L.J., Flory J.D., Siever L.J. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 2010, 35(6):1356-1362.
41. Meehl P.E. Schizotaxia revisited. Arch. Gen. Psychiatry 1989, 46(10):935-944.
42. Mehta M.A., Sahakian B.J., McKenna P.J., Robbins T.W. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berl.) 1999, 146(2):162-174.
43. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162(3):495-506.
44. Miller D.D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim. Care Companion J. Clin. Psychiatry 2004, 6(Suppl. 2):3-7.
45. Mitropoulou V., Harvey P.D., Maldari L.A., Moriarty P.J., New A.S., Silverman J.M., Siever L.J. Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity. Biol. Psychiatry 2002, 52(12):1175-1182.
46. Moritz S., Woodward T.S., Chen E. Investigation of metamemory dysfunctions in first-episode schizophrenia. Schizophr. Res. 2006, 81(2-3):247-252.
47. Nelson H., O'Connell A. National Adult Reading Test (NART) Test Manual 1991, NFER-Nelson, Windsor.
48. Newhouse P.A., Potter A., Singh A. Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol. 2004, 4(1):36-46.
49. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72(1):29-39.
50. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165(2):203-213.
51. Park S., McTigue K. Working memory and the syndromes of schizotypal personality. Schizophr. Res. 1997, 26(2-3):213-220.
52. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., Breier A., Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry 2000, 57(3):249-258.
53. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr. Bull. 1991, 17(4):555-564.
54. Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annu. Rev. Clin. Psychol. 2006, 2:291-326.
55. Raine A., Reynolds C., Lencz T., Scerbo A., Triphon N., Kim D. Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality. Schizophr. Bull. 1994, 20(1):191-201.
56. Raine A., Lencz T., Mednick S.A. Schizotypal Personality 1995, Cambridge University Press.
57. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68(1):29-39.
58. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., Kester D.B., Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch. Gen. Psychiatry 1991, 48(7):618-624.
59. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., Oblin A., Gonon F., Carter C., Benavides J., Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280(1):83-97.
60. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33. quiz 34-57.
61. Siever L.J., Koenigsberg H.W., Harvey P., Mitropoulou V., Laruelle M., Abi-Dargham A., Goodman M., Buchsbaum M. Cognitive and brain function in schizotypal personality disorder. Schizophr. Res. 2002, 54(1-2):157-167.
62. Tek C., Gold J., Blaxton T., Wilk C., McMahon R.P., Buchanan R.W. Visual perceptual and working memory impairments in schizophrenia. Arch. Gen. Psychiatry 2002, 59(2):146-153.
63. Thoma P., Zoppelt D., Wiebel B., Daum I. Recollection and familiarity in negative schizophrenia. Neuropsychologia 2006, 44(3):430-435.
64. Trestman R.L., Keefe R.S., Mitropoulou V., Harvey P.D., deVegvar M.L., Lees-Roitman S., Davidson M., Aronson A., Silverman J., Siever L.J. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res. 1995, 59(1-2):127-136.
65. Tsuang M.T., Stone W.S., Tarbox S.I., Faraone S.V. An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophr. Res. 2002, 54(1-2):169-175.
66. White H.K., Levin E.D. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl.) 2004, 171(4):465-471.
67. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376(6541):572-575.